Shots:

• The companies collaborate to accelerate the development of BioNTech’s BNT162- which is anticipated to enter clinical studies by the end of Apr’2020. The alliance will leverage the expertise and resources of both companies to co-develop mRNA-based vaccine candidate globally (Ex- China)
• The collaboration follows 2018 agreement signed b/w the companies to develop mRNA-based vaccines against influenza
• The companies have implemented a material transfer and collaboration agreement that enable them to start working together immediately and will finalize financial terms over the next few weeks

Click here to­ read full press release/ article | Ref: Pfizer | Image: The Economic Times